Journal Article

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Filipits, Martin, Sabatier, Laure, Soria, Jean-Charles, Haddad, Vincent, Taranchon, Estelle, Dunant, Ariane, Le Chevalier, Thierry, Stahel, Rolf, Fouret, Pierre, André, Fabrice, Pignon, Jean-Pierre, Tursz, Thomas, Pirker, Robert, Olaussen, Ken A, Brambilla, Elisabeth, Popper, Helmut H

2006

Overview

Tumor specimens from patients in a trial of cisplatin-based adjuvant chemotherapy for non–small-cell lung cancer were analyzed for the presence of ERCC1, an enzyme that participates in the repair of DNA damage caused by cisplatin. The absence of ERCC1 in the tumor was associated with a survival benefit from cisplatin-based adjuvant chemotherapy, whereas patients whose tumor expressed the enzyme failed to benefit from the chemotherapy. The absence of ERCC1 in the tumor was associated with a survival benefit from cisplatin-based adjuvant chemotherapy, whereas patients whose tumor expressed the enzyme failed to benefit from the chemotherapy. Lung cancer is a leading cause of death from cancer in most industrialized countries. 1 Despite undergoing complete resection of non–small-cell lung cancer, 33% of patients with pathological stage IA die within 5 years, as do 77% of those with pathological stage IIIA. 2 Clinical trials have tested the ability of adjuvant chemotherapy to improve survival after complete resection of non–small-cell lung cancer. The International Adjuvant Lung Cancer Trial (IALT) demonstrated an absolute benefit of 4.1% in 5-year overall survival among 1867 patients who were treated with adjuvant cisplatin-based chemotherapy. 3 Several other randomized studies have confirmed the benefit of postoperative platinum-based therapy . . .

• Publisher: Massachusetts Medical Society
• Subject: Adult / Aged / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Biological and medical sciences / Biomarkers, Tumor - genetics / Biomarkers, Tumor - metabolism / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - metabolism / Carcinoma, Non-Small-Cell Lung - mortality / Chemotherapy / Chemotherapy, Adjuvant / Cisplatin - administration & dosage / Combined Modality Therapy / DNA Repair / DNA, Neoplasm - metabolism / DNA-Binding Proteins - genetics / DNA-Binding Proteins - metabolism / Drug Resistance, Neoplasm - genetics / Endonucleases - genetics / Endonucleases - metabolism / Female / General aspects / Humans / Lung cancer / Lung Neoplasms - drug therapy / Lung Neoplasms - metabolism / Lung Neoplasms - mortality / Male / Medical sciences / Middle Aged / Pneumology / Proportional Hazards Models / RNA, Messenger - metabolism / Studies / Survival Rate / Tumors of the respiratory system and mediastinum